Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-41.5
％Wording
Definitive
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 12 May 2025Net SalesConsolidated127,000→126,257Millions of yen (change rate: %)
-0.6%
Net SalesIndividual111,100→110,934Millions of yen (change rate: %)
-0.1%
Operating profitConsolidated6,100→3,567Millions of yen (change rate: %)
-41.5%
Operating profitIndividual6,300→4,285Millions of yen (change rate: %)
-32.0%
Ordinary incomeConsolidated6,300→4,031Millions of yen (change rate: %)
-36.0%
Ordinary incomeIndividual6,800→5,048Millions of yen (change rate: %)
-25.8%
Profit attributable to owners of the parentConsolidated4,800→3,448Millions of yen (change rate: %)
-28.2%
Profit attributable to owners of the parentIndividual5,100→4,183Millions of yen (change rate: %)
-18.0%
Net income per shareConsolidated83.55→60.03yen and sen (change: %)
-28.2%
Net income per shareIndividual88.76→72.82yen and sen (change: %)
-18.0%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
A decrease in gross profit resulting from sales of certain core products and other items falling below forecast, the recognition of upfront contractual payments for in-licensed products as research and development expenses, and other factors.
Previous-period resultsConsolidated Net Sales 130,087 / Operating profit 12,567 / Ordinary income 13,219 / Profit attributable to owners of the parent 9,086 / Net income per share 158.17 / Individual Net Sales 115,918 / Operating profit 12,902 / Ordinary income 13,706 / Net income for the current fiscal year 9,382 / Net income per share 163.29
Consolidated / non-consolidatedConsolidated / non-consolidated (standalone)
| Item | Details |
|---|---|
| Net Sales | Consolidated 127,000 / Individual 111,100 → Consolidated 126,257 / Individual 110,934（Consolidated -0.6 / Individual -0.1） |
| Operating profit | Consolidated 6,100 / Individual 6,300 → Consolidated 3,567 / Individual 4,285（Consolidated -41.5 / Individual -32） |
| Ordinary income | Consolidated 6,300 / Individual 6,800 → Consolidated 4,031 / Individual 5,048（Consolidated -36 / Individual -25.8） |
| Profit attributable to owners of the parent | Consolidated 4,800 / Individual 5,100 → Consolidated 3,448 / Individual 4,183（Consolidated -28.2 / Individual -18） |
| Net income per share | Consolidated 83.55 / Individual 88.76 → Consolidated 60.03 / Individual 72.82（Consolidated -28.2 / Individual -18） |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 May 2025 |
| Previous-period results | Consolidated Net Sales 130,087 / Operating profit 12,567 / Ordinary income 13,219 / Profit attributable to owners of the parent 9,086 / Net income per share 158.17 / Individual Net Sales 115,918 / Operating profit 12,902 / Ordinary income 13,706 / Net income for the current fiscal year 9,382 / Net income per share 163.29 |
| Reason for the revision | A decrease in gross profit resulting from sales of certain core products and other items falling below forecast, the recognition of upfront contractual payments for in-licensed products as research and development expenses, and other factors. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to sales of certain core products and other items falling below forecast, profits were below forecast due to a decrease in gross profit and the recognition of upfront contractual payments for in-licensed products as research and development expenses, among other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.